Efeitos da aprotinina em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea / Effects of aprotinin in children with acianogenic congenital heart disease submitted to correction with extracorporeal circulation
AUTOR(ES)
Cesar Augusto Ferreira
DATA DE PUBLICAÇÃO
2006
RESUMO
Introduction. Aprotinin seems to reduce the need for transfusion, the inflammatory process and myocardial damage after extracorporeal circulation (ECC). Material and Methods. A prospective randomized study was conducted on children aged 30 days to 4 years submitted to correction of acyanogenic congenital heart disease with ECC and divided into two groups: Control (n=9) and Aprotinin (n=10). In the Aprotinin Group the drug was administered immediately before ECC and the systemic inflammatory response and hemostatic and multiorgan dysfunctions were analyzed on the basis of clinical and biochemical markers. Differences were considered to be significant when P<0.05. Results. The groups were similar regarding demographic and intraoperative variables, except for a greater hemodilution in the Aprotinin Group. The drug had no benefit regarding time of mechanical pulmonary ventilation, permanence in the postoperative ICU and length of hospitalization, or regarding the use of inotropic drugs and renal function. The partial arterial oxygen pressure/inspired oxygen fraction ratio (PaO2/FiO2) was significantly reduced 24 h after surgery in the Control Group. Platelet concentration was preserved with the use of Aprotinin, whereas thrombocytopenia occurred in the Control Group since the beginning of ECC. Blood loss was similar for both groups. Significant leukopenia was observed in the Aprotinin Group during ECC, followed by leukocytosis. Tumor necrosis factor alpha (TNF-), interleukins (IL)-6, IL-8, IL-10, IL-6/IL-10 ratio, cardiac troponin I (cTnI), creatine kinase MB fraction (CKMB), glutamic-oxaloacetic transaminase (GOT) and the aminoterminal fraction of natriuretic peptide type B (NT-proBNP) ndid not differ significantly between groups.The postoperative IL-6/IL-10 fraction increased significantly in the Control Group. Post-ECC blood lactate concentration and metabolic acidosis was more intense in the Aprotinin Group. There were no complications with the use of Aprotinin. Conclusion. Aprotinin did not minimize the clinical manifestations or serum markers of the inflammatory, systemic and myocardial response, but quantitatively preserved the platelets.
ASSUNTO(S)
aprotinina pediatric cardiac surgery systemic inflammatory response syndrome (sirs) síndrome da resposta inflamatória sitêmica (sris) proteção miocárdica. systemic capillary leak syndrome (scls) myocardial protection. circulação extracorpórea (cec) aprotinin síndrome do extravasamento capilar sistêmico (secs) cirurgia cardíaca pediátrica extracorporeal circulation (ecc)
Documentos Relacionados
- Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea?
- Avaliação da aprotinina na redução da resposta inflamatória sistêmica em crianças operadas com circulação extracorpórea
- Aprotinina não influencia troponina I, NTproBNP e função renal em crianças operadas com circulação extracorpórea
- Avaliação e intervenção motora em crianças portadoras de cardiopatia congênita
- Saturação periférica de oxigênio, frequência cardíaca e pressão arterial sistêmica em crianças portadoras de cardiopatia congênita cianogênica com hipofluxo pulmonar durante procedimento odontológico